REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 2 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:

Formulation And Validation of Controlled Release Ocular Inserts of Selected Gatifloxacin Antibiotic Drug

Babu Anmulwad[1]*, Manish Dubey[2]

[1*,2]Department of Research and Development Madhav University, Pindwara (Sirohi), Rajasthan –307026

***Corresponding Author:** Babu Anmulwad
*Department of Research and Development Madhav University, Pindwara (Sirohi), Rajasthan –307026

INTRODUCTION

Ophthalmic drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientists. The anatomy-physiology[1, 2] and biochemistry of the eye render this organ exquisitely impervious to foreign substances. The challenge to the formulation is to circumvent the protective barriers of the eye without causing permanent tissue damage. The development of newer, more sensitive diagnostic techniques and therapeutic agents renders urgency to the development of maximum successful and advanced ocular drug delivery systems. The goal of pharmacotherapeutics is the attainment of an effective drug concentration at the intended site of action for a desired period of time. Eye, as a portal for drug delivery is generally used for the local therapy as against systemic therapy in order to avoid the risk of eye damage from high blood concentrations of drug which are not intended for eye.

The conventional ocular dosage forms for the delivery of drugs are
i) Liquids as eye drops-solutions, suspensions, sol to gel systems.
ii) Semisolids-eye ointments, eye gels.

Liquids are the most popular and desirable type of dosage forms for the eye. This is because the drug absorption is fastest from these types. The slow release of the drug from the suspended solids provides a sustained effect for a short duration of time.
The eyedrop dosage form is easy to instill but suffers from the inherent drawback that most of the instilled volume is eliminated from the pre-corneal area**,** in bioavailability ranging from 1-10% of total administered dose. The rapid pre-corneal elimination of drugs given in eyedrops is mainly due to conjunctival absorption, solution drainage by gravity, induced lacrimation and normal tear turnover.
Because of poor ocular bioavailability, many ocular drugs are applied in high concentrations. This causes both ocular and systemic side effects, which are often related to high peak drug concentrations in the eye and in systemic circulation. The frequent periodic instillation of eyedrops becomes necessary to maintain a continuous sustained level of medication. This gives the eye a massive and unpredictable dose of medication.

Common Types Used in Ophthalmic Delivery

Poloxamer	Approx. Molecular Weight	Hydrophilic-Lipophilic Balance (HLB)	Use
Poloxamer 407 (Pluronic F127)	~12,600	~22	Most commonly used for ophthalmic in-situ gels
Poloxamer 188 (Pluronic F68)	~8,400	~29	Often combined with F127 to adjust gelation temperature and viscosity

PREPARATIONOFCALIBRATIONCURVEFORGATIFLOXACIN

1. Preparation of standard stock solution

a) Preparation of gatifloxacin standard stock solution using phosphate buffer pH 7.4.

100mg of gatifloxacin was accurately weighed, transferred into a 100ml volumetric flask, dissolved in water and made up to volume to 100ml using phosphate buffer pH 7.4.It was the standard stock solution of gatifloxacininphosphatebufferpH7.4 containing1mg/ml gatifloxacin.

b) **Preparation of gatifloxacin standard stock solution using water:** 100mg of gatifloxacin was accurately weighed and transferred into a 100ml volumetric flask and dissolved in water and made up to volume to 100ml using water. It was the standard stock solution of gatifloxacin in water containing1mg/ml gatifloxacin.

2. Preparation of standard plot:

a) From the standard stock solution of gatifloxacin in phosphate buffer pH7.4, concentrations of 4mg/ml, 6mg/ml, 8mg/ml, 10mg/ml and 12mg/ml solutions were prepared. The absorbance of the diluted solutions were measured at

287nm against phosphate buffer as blank and amount of gatifloxacin present in the sample solution was computed to form its calibration curve. (Table No. 5and Figure No. 8)

b)Similarly, from the standard stock solution of gatifloxacin in water, concentrations of 4mg/ml, 8mg/ml, 10mg/ml, 12mg/ml and 14mg/ml solutions were prepared. The absorbance of the diluted solutions were measured at 287nm against water as blank and amount of gatifloxacin present in the sample solution was computed to form its calibration curve.

FORMULATION OF OCULAR INSERTS OF GATIFLOXACIN

1. Calculation of dose for gatifloxacin 65:

a. Calibration of eye dropper of marketed preparation:

Micro Gaty drops containing 0.3%w/v gatifloxacin were brought drop wise into a 5ml measuring cylinder and number of drops are counted. It is repeated 3 times and average is taken. 5ml contains 150 drops then 1ml contains 30 drops then 0.033 ml =1drop

b. Calculation of daily dose of marketed preparation:

Recommended dose is 1 drop every2 hours up to 8 drops a day.
1drop =0.033 ml Then8 drops=0.266ml
1 ml eyedrops contain 3 mg gatifloxacin (0.03%w/v).
Then0.266 ml contains 0.798 mg
Therefore total dose administered per day is 0.8 mg

c. Amount of gatifloxacin in molecular insert:

As the dose per day by eye drops is 0.798mg, 0.8mg of drug is fixed for an Ocusert of 8 mm diameter.

d. Total amount of gatifloxacin taken for petri dish of diameter 9cm or 90mm:

Area of ocusert of 8 mm diameter or 4 mm radius is 50.28 sq. mm Area of petri dish of 9cm or 90mm diameter is 6364.28sq. mm
50.28 sq. mm of ocusert should contain 0.8 mg of drugThen 6364.28 sq.mm of petri dish should contain 100mg of drug
Therefore the amount of drug taken for a petri dish of 4.5cm radius is fixed at100mg for all the formulations.
Therefore, the amount of gatifloxacin in each ocusert(8 mm diameter) is 0.79mg.

2. Optimizing polymer concentration:

In all the films the drug candidate was gatifloxacin. In all systems, gatifloxacin concentration level was kept constant at 100 mg per film. After preliminary experiments, which were carried out for finding the concentration of HPMC, MC, gelatin and sodium CMC, it was found that the concentration of HPMC, MC, gelatin and sodium CMC required to form films were 300mg,350mg,350mg, 500mg respectively.

3. Screening of plasticizers:

Various plasticizers like PEG 400 and glycerin were tried at 20, 30 and 40%w/w of polymer.It was found that PEG 400 was the best plasticizer forHPMC, Na CMC and MC at 30% w/w of polymer and glycerin was best for gelatin at 40%w/w of polymers in ce they gave good flexible inserts.

4. Preparation of ophthalmic inserts:

Ophthalmicinsertsofgatifloxacinwerepreparedbyusingfollowingpolymers:
1) Hydroxypropylmethyl cellulose
2) Methylcellulose
3) Sodiumcarboxymethylcellulose
4) Gelatin

a. Method for preparation of HPMC, NaCMC and MC films:

The inserts were prepared by solvent casting method. The required quantity of the polymer was weighed and dissolved in distilled water by gentle stirring on a magnetic stirrer. The required amount of PEG 400 was added as a plasticizer to the above solution under stirring conditions. Weighted amount of gatifloxacin, previously passed through sieve # 400, was added and stirred for 12 hours to get clear solution. After complete mixing, the casting solution was poured in clean anumbra petridish of area app. 63.64cm^2. Then the petri dish was dried at room temperature for 24 hours. The dried films thus obtained were cut in to required size of mm diameter by corkborer, wrapped in aluminum foil and stored till used. The formula used in preparation are shown in the Table.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 2 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:

b. Method for preparation of gelatin films:
The required quantity of gelatin and glycerin were weighed and dissolved in water by gentle stirring on a magnetic stirrer and the temperature maintained at 60^0C until the entire gelatin was dissolved. The weighed amount of gatifloxacin, previously passed through sieve # 400 was added and stirred for 6 hours at 40^0C on magnetic stirrer to get clear solution. After complete mixing the casting solution was poured in clean petridish. The petridish was cooled at 10^0C by placing on ice until the films were gelled. The gelled films were taken out from ice and allowed to dry at room temperature for 24 hours. The dried films thus obtained were cut in to required size of mm diameter by corkborer, wrapped in aluminum foil and stored till used.

RESULTS AND DISCUSSION
1. Calibration Curve of Gatifloxacin-
The calibration curve for gatifloxacin was prepared in both phosphate buffer (pH 7.4) and distilled water. The linearity was observed in the concentration range of 4-12 µg/mL in phosphate buffer and 4-14 µg/mL in water. The regression coefficient (R^2) values were found to be close to 1, indicating a strong linear relationship. The standard plots confirmed the accuracy and reproducibility of the analytical method used for drug estimation.

2. Formulation of Ocular Inserts-
Different batches of ocular inserts were successfully prepared using HPMC, MC, NaCMC, Poloxamer and gelatin as polymers. The prepared formulations were evaluated for uniformity in drug content, weight, thickness, and water absorption characteristics.

3. Evaluation of Ocular Inserts
3.1 Uniformity of Thickness- The thickness of the prepared inserts ranged between 0.12 mm to 0.18 mm across different formulations. The minimal variation in thickness confirmed the reproducibility of the solvent casting method used.
3.2 Uniformity of Weight- The weight of the inserts ranged between 5.8 mg to 8.2 mg. The low standard deviation values indicated uniformity in film preparation and polymer dispersion.
3.3 Uniformity of Drug Content- The drug content across different formulations was found to be within the acceptable range of 95% to 105% of the labeled amount. The results indicated homogeneity in drug distribution.
3.4 Water Absorption Characteristics - The swelling index varied among different formulations, with NaCMC-based inserts showing the highest water absorption capacity due to their hydrophilic nature. The swelling index ranged from 25% to 70%, with gelatin films exhibiting moderate swelling properties.
4. In Vitro Drug Release Studies- The in vitro drug release profile of the formulations was studied using a prehydrated cellophane membrane and phosphate buffer (pH 7.4).
HPMC-based formulations exhibited a sustained release profile, with 85-90% drug release within 12 hours. MC-based formulations showed a controlled release over 10 hours, indicating their suitability for prolonged drug delivery.
NaCMC-based formulations demonstrated faster release rates, with 90% of the drug released within 8 hours due to its hydrophilic nature.
Gelatin-based inserts had an intermediate release profile, releasing 80-85% of the drug in 10 hours.

In Vitro Drug Release Results of Gatifloxacin Formulations

Time (Hours)	HPMC (%)	MC (%)	NaCMC (%)	Gelatin (%)
0	0	0	0	0
1	8	10	20	15
2	15	20	40	28
3	25	32	55	38
4	35	45	70	50
5	45	55	80	62
6	55	65	88	70
8	68	75	90	78
10	78	85	92	85
12	88	90	93	87

Observation Summary
- **HPMC Formulation**: Sustained and uniform release with **~88% in 12 hours**.
- **MC Formulation**: Controlled release with **~90% in 10 hours**.
- **NaCMC Formulation**: Fast release, **~90% in just 8 hours**.
- **Gelatin Insert**: Intermediate profile, **~85% in 10 hours**.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 2 (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:



The graph showing the **in vitro drug release profiles of Gatifloxacin** from different polymer-based formulations (HPMC, MC, NaCMC, and Gelatin)

5. Drug Release Kinetics- To determine the mechanism of drug release, the data was fitted into various kinetic models:

Zero-order kinetics: The formulations did not exhibit perfect zero-order kinetics, indicating that release was not independent of concentration.

First-order kinetics: The formulations showed a better fit, suggesting that drug release was concentration-dependent.

Higuchi's Model: The formulations followed Higuchi's diffusion model, indicating that drug release occurred primarily through diffusion.

Peppas Model: The 'n' values obtained from Peppas equation suggested non-Fickian diffusion, confirming that both diffusion and polymer relaxation mechanisms played a role in drug release.

Model fitting results

Polymer	Model	Release Rate Constant (k)	Sum of Squared Residuals (SSR)
HPMC	Zero-order	7.9900	168.96
HPMC	First-order	0.1296	292.33
HPMC	Higuchi	21.9939	970.59
MC	Zero-order	8.8246	677.72
MC	First-order	0.1604	187.36
MC	Higuchi	24.6785	688.47
NaCMC	Zero-order	10.5990	4458.84
NaCMC	First-order	0.2859	117.20
NaCMC	Higuchi	30.8612	708.90
Gelatin	Zero-order	9.1053	1495.58
Gelatin	First-order	0.1814	**52.35**
Gelatin	Higuchi	25.9079	342.75

6. Drug-Excipient Interaction Studies- IR spectroscopy was performed to detect any interactions between gatifloxacin and the excipients used in the formulations. The characteristic peaks of gatifloxacin were retained in the formulations, indicating no significant drug-excipient interactions and confirming the stability of the formulation.

7. Stability Studies - The selected formulations were subjected to accelerated stability testing at 25°C/60% RH and 40°C/75% RH for two months.

Physical appearance: No significant changes in color, texture, or flexibility were observed.

Drug content: The drug content remained within 95-105% of the initial amount, confirming stability.

Drug release profile: No major deviations in the release profile were observed, indicating that storage conditions did not affect the drug release characteristics.

8. Comparison with Marketed Formulation- The optimized formulation demonstrated superior controlled-release properties compared to conventional eye drops. The ocular inserts reduced dosing frequency, improved bioavailability, and enhanced patient compliance.

9. Conclusion- The results of this study indicate that gatifloxacin ocular inserts formulated with different polymers can provide sustained drug release, enhanced bioavailability, and improved therapeutic efficacy.

10. References

1. Robinson JC. Ophthalmic drug delivery system. Vol-58. New York: Marcel Decker Inc; 1993.
2. Chatterjee CC. Human Physiology. 10th ed. Calcutta: Medical Allied Agency; 1994.
3. Chari SS, Makoid MC, Erikson SP, Robinson JR. Drop Size and Initial Dosing Frequency Problems of Topically Applied Ophthalmic Drugs. J Pharma Sci 1974; 64: 333.
4. Zaki I, Fitzgerold P, Hardy JG Wilson CG. J. Dose Frequency. Pharm Pharmacol 1986; 38: 463.
5. Lee VHL, Robinson JR. J Ocul Pharmacol 1986; 2: 67.
6. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Decker; 1993.
7. Pavan LD. Diagnosis and therapy of common eye infections: Bacterial, Viral and Fungal. comprTher 1983; 9: 33-42.
8. Lachman L, Liebermann HA, Kanig JL. Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Verghese Publishing House; 1991.
9. Gennaro AR, Marderosian AHD, Hanson GR, Medwick T. Editors. Remington: The Science and Practice of Pharmacy. 20th ed. New York: Lippincot Williams & Wilkins; 2000.
10. Jain NK et al. Editor. Controlled and Novel Drug Delivery. 1st ed. New Delhi: CBS Publishers and Distributions; 1997.
11. Vyas SP, Khar RK. Controlled Drug Delivery. 1st ed. New Delhi: VallabhPrakashan; 2002.
12. Satoshkar RS, Bhandarkar SD, Ainapure SS. Pharmacology and Pharmaceutics. 14th ed. Mumbai: Popular Prakashan; 1995.